

Thomson Medical Group Limited and its Subsidiaries

Independent auditor's report For the financial year ended 30 June 2025

Independent auditor's report to the members of Thomson Medical Group Limited

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Thomson Medical Group Limited (the Company) and its subsidiaries (collectively, the Group), which comprise the statements of financial position of the Group and Company as at 30 June 2025, the statements of changes in equity of the Group and Company, and the consolidated statement of profit or loss, consolidated statement of comprehensive income and consolidated statement of cash flows of the Group for the financial year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying consolidated financial statements of the Group, the statement of financial position and the statement of changes in equity of the Company are properly drawn up in accordance with the provisions of the Companies Act 1967 (the Act) and Singapore Financial Reporting Standards (International) (SFRS(I)) so as to give a true and fair view of the consolidated financial position of the Group and the financial position of the Company as at 30 June 2025 and of the consolidated financial performance, consolidated changes in equity and consolidated cash flows of the Group and changes in equity of the Company for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with Singapore Standards on Auditing (SSAs). Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Group in accordance with the Accounting and Corporate Regulatory Authority (ACRA) *Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities* (ACRA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled our responsibilities described in the *Auditor's responsibilities for the audit of the financial statements* section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying financial statements.

Thomson Medical Group Limited and its Subsidiaries

Independent auditor's report For the financial year ended 30 June 2025

Independent auditor's report to the members of Thomson Medical Group Limited

Key audit matters (cont'd)

Valuation of assets acquired, liabilities assumed and goodwill arising from the acquisition of Far East Medical Vietnam Limited

On 21 December 2023, the Group completed its acquisition of 100% of the equity interest in Far East Medical Vietnam Limited ("FEMVN") for a purchase consideration of \$469,071,000. The acquisition of FEMVN was accounted for using the acquisition method and the Group performed a purchase price allocation ("PPA") exercise as disclosed in Note 16 to the financial statements. The fair values of the total assets acquired, liabilities assumed and resultant goodwill arising from the acquisition, adjusted upon the completion of the PPA amounted to \$107,560,000, \$22,704,000 and \$384,215,000, respectively.

Significant judgement and estimates were made in the PPA exercise on the identification of intangible assets, valuation of the assets acquired, and liabilities assumed arising from the acquisition. Given the quantitative materiality of this acquisition and the significant management judgement required in the PPA exercise, we considered the accounting for the acquisition of FEMVN as a key audit matter.

Our audit procedures included, amongst others, reading the transaction agreement to obtain an understanding of the transaction and key terms. We evaluated the objectivity, competence and capability of the independent valuers engaged by the management by considering their professional background and experiences. We also engaged our internal valuation specialists to assist us in reviewing the appropriateness of the valuation method and key assumptions used in the valuation.

In addition, we assessed the adequacy of the disclosures in notes to the financial statements as they are related to investment in subsidiaries and goodwill in Note 2.4(b) Business combinations, Note 2.8 and Note 13 Intangible assets, Note 2.11 Impairment of non-financial assets, Note 2.12 Subsidiaries, Note 3(a) Impairment of goodwill, Note 16 Investment in subsidiaries, and Note 37 Prior year adjustments.

Carrying value of goodwill attributable to Thomson Medical Pte Ltd, TMC Life Sciences Berhad and Far East Medical Vietnam Limited

As at 30 June 2025, the carrying value of the Group's goodwill arising from the acquisition of Thomson Medical Pte Ltd (TMPL), TMC Life Sciences Berhad (TMCLS) and Far East Medical Vietnam Limited (FEMVN) amounted to \$379,788,000, \$40,794,000 and \$309,081,000, respectively.

For the purpose of the impairment assessment, management has identified TMPL, TMCLS and FEMVN as separate cash-generating units ("CGU") to which the goodwill has been allocated. Impairment assessment is carried out annually and whenever there is an indication that the carrying value of the CGU may be impaired.

Management has prepared cash flow projections from financial budgets to assess the recoverable amounts of the CGUs which principally engaged in healthcare services. This assessment requires management to make judgements over certain key inputs for the projections in relation to revenue growth rates, terminal growth rate and discount rate.

Given the magnitude of the carrying value of the CGUs and significant judgement and estimation involved in assessing the recoverable amounts, we have identified this as a key audit matter.

Thomson Medical Group Limited and its Subsidiaries

Independent auditor's report For the financial year ended 30 June 2025

Independent auditor's report to the members of Thomson Medical Group Limited

Key audit matters (cont'd)

Carrying value of goodwill attributable to Thomson Medical Pte Ltd, TMC Life Sciences Berhad and Far East Medical Vietnam Limited (cont'd)

Our audit procedures included, amongst others, obtaining an understanding of the relevant internal controls over the estimation of the recoverable amount of the CGUs and evaluating management's key assumptions on revenue growth rates and terminal growth rate, by taking into consideration the current and expected future economic conditions. We determined the reasonableness of the pre-tax discount rate used to determine the present value of the recoverable amount of all CGUs with the assistance of our internal valuation specialist. We further reviewed management's sensitivity analysis of the recoverable amount to reasonable changes in the key assumptions.

In addition, we assessed the adequacy of the disclosures in notes to the financial statements as they are related to goodwill in Note 2.4(b) Business combinations, Note 2.8 and Note 13 Intangible assets, Note 2.11 Impairment of non-financial assets, and Note 3(a) Impairment of goodwill.

Carrying value of goodwill and property and equipment attributable to BB Waterfront Sdn Bhd

As at 30 June 2025, the carrying value of the Group's goodwill arising from the acquisition of BB Waterfront Sdn Bhd (BBWF) amounted to \$58,396,000. The carrying value of BBWF's property and equipment, which comprised mainly freehold land located in Johor Bahru, Malaysia, amounted to \$83,944,000. The aggregate value of goodwill and property and equipment attributable to BBWF represented 8.0% of the Group's total assets.

For the purpose of the impairment assessment, management has identified BBWF as a cash-generating unit ("CGU") to which the goodwill and property and equipment have been allocated. Impairment assessment is carried out annually and whenever there is an indication that the carrying value of the CGU may be impaired.

Management has prepared cash flow projections from financial budgets to assess the recoverable amount of BBWF which will principally be engaged in healthcare services. This assessment requires management to make judgements over certain key inputs for the projections in relation to revenue growth rates, terminal growth rate and discount rate.

Given the magnitude of the carrying value of the CGU and significant judgement and estimation involved in assessing the recoverable amount of BBWF, we have identified this as a key audit matter.

Our audit procedures included, amongst others, obtaining an understanding of the relevant internal controls over the estimation of the recoverable amount of the CGU and evaluating management's key assumptions on revenue growth rates and terminal growth rate, by taking into consideration the current and expected future economic conditions. We also compared these key assumptions against past actual outcomes of another subsidiary of the Group which operates in similar industry. We determined the reasonableness of the pre-tax discount rate used to determine the present value of the recoverable amount of BBWF with the assistance of our internal valuation specialist. We further reviewed management's sensitivity analysis of the recoverable amount to reasonable changes in the key assumptions.

In addition, we assessed the adequacy of the disclosures in notes to the financial statements as they are related to goodwill and property and equipment in Note 2.4(b) Business combinations, Note 2.7 and Note 12 Property and equipment, Note 2.8 and Note 13 Intangible assets, Note 2.11 Impairment of non-financial assets, Note 3(a) Impairment of goodwill and Note 3(b) Impairment of property and equipment attributable to BBWF.

Thomson Medical Group Limited and its Subsidiaries

Independent auditor's report For the financial year ended 30 June 2025

Independent auditor's report to the members of Thomson Medical Group Limited

Key audit matters (cont'd)

Carrying value of investment properties and development property located in Johor Bahru, Malaysia

As at 30 June 2025, the Group's investment properties and development property located in Johor Bahru, Malaysia, amounted to \$136,419,000 and \$128,940,000 respectively, which in aggregate represented 14.9% of the Group's total assets. Investment properties, except for freehold land, are carried at cost less accumulated depreciation and accumulated impairment losses, whilst development property is carried at the lower of cost and net realisable value (NRV). Freehold land has an indefinite useful life and therefore is not depreciated. During the financial year ended 30 June 2025, the Group reversed an impairment loss of \$28,024,000 and \$26,593,000 in respect of the investment properties and development property respectively.

The carrying amounts of these assets are reviewed annually by management to assess whether there are indicators of impairment or reversal of impairment. Management assessed the recoverable amount of the investment properties and the NRV of the development property based on valuations obtained from an independent valuer. These valuations involve various underlying assumptions and techniques used by the independent valuer, including adjustments made associated with the property market and economic conditions prevailing at the reporting date.

Given the magnitude of these assets and significant judgement associated with the inputs used in valuation, we have identified the carrying value of investment properties and development property located in Johor Bahru, Malaysia, as a key audit matter.

Our audit procedures included, amongst others, reviewing management's assessment of the recoverable amount of the investment properties and the NRV of the development property. This includes evaluating the objectivity, competence and capability of management's independent valuer. We also involved our internal valuation specialist in assessing the appropriateness of the valuation method and key assumptions used in the valuations. We compared them to available industry data and comparable market transactions of properties in the vicinity, taking into account the size and location of the investment properties and development property with the assistance of our internal valuation specialist. We also reviewed the adjustments made to the industry data, taking into consideration the property market and economic conditions prevailing at the reporting date. We have also recomputed the reversal of impairment loss arising from the increase in recoverable amount of the investment properties and development property.

We also assessed the adequacy of the disclosures in notes to the financial statements as they are related to investment properties and development property in Note 2.9 and Note 14 Investment properties, Note 2.10 and Note 20 Development property, Note 2.11 Impairment of non-financial assets, Note 3(c) Impairment of investment properties and development property, and Note 32 Fair value of assets and liabilities.

Thomson Medical Group Limited and its Subsidiaries

Independent auditor's report For the financial year ended 30 June 2025

Independent auditor's report to the members of Thomson Medical Group Limited

Other information

Management is responsible for other information. The other information comprises the information included in the annual report, but does not include the financial statements and our auditor's report thereon, which we obtained prior to the date of this auditor's report, except for the Statistics of Shareholdings, which is expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the Statistics of Shareholdings, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take appropriate actions in accordance with SSAs.

Responsibilities of management and directors for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and SFRS(I), and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Group's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Thomson Medical Group Limited and its Subsidiaries

Independent auditor's report For the financial year ended 30 June 2025

Independent auditor's report to the members of Thomson Medical Group Limited

Auditor's responsibilities for the audit of the financial statements (cont'd)

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the consolidated financial statements. We are responsible for the direction, supervision and review of the audit work performed for the purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Thomson Medical Group Limited and its Subsidiaries

**Independent auditor's report
For the financial year ended 30 June 2025**

Independent auditor's report to the members of Thomson Medical Group Limited

Report on other legal and regulatory requirements

In our opinion, the accounting and other records required by the Act to be kept by the Company and by those subsidiary corporations incorporated in Singapore of which we are the auditors have been properly kept in accordance with the provisions of the Act.

The engagement partner on the audit resulting in this independent auditor's report is Tan Peck Yen.

A handwritten signature in black ink, appearing to read "Ernst & Young LLP", is written over a faint, rectangular stamp that also contains the text "Ernst & Young LLP".

Public Accountants and
Chartered Accountants
Singapore

29 August 2025